Xlife Sciences (XLS) Stock Overview
Focuses on the development and commercialization of research projects in the life sciences sector. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
XLS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Xlife Sciences AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 22.50 |
| 52 Week High | CHF 28.40 |
| 52 Week Low | CHF 16.25 |
| Beta | 0.34 |
| 1 Month Change | -15.73% |
| 3 Month Change | 19.36% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | -56.73% |
| Change since IPO | -31.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| XLS | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -5.1% | -2.7% | -0.7% |
| 1Y | n/a | -19.0% | 8.7% |
Return vs Industry: Insufficient data to determine how XLS performed against the German Life Sciences industry.
Return vs Market: Insufficient data to determine how XLS performed against the German Market.
Price Volatility
| XLS volatility | |
|---|---|
| XLS Average Weekly Movement | 11.1% |
| Life Sciences Industry Average Movement | 5.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 13.4% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: XLS's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: XLS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 17 | Oliver Baumann | www.xlifesciences.ch |
Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company’s project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also produces, researches, develops, and manufactures the chemical and active pharmaceutical ingredients for human and veterinary medicines; and offers clinical research organization services.
Xlife Sciences AG Fundamentals Summary
| XLS fundamental statistics | |
|---|---|
| Market cap | €132.04m |
| Earnings (TTM) | €33.53m |
| Revenue (TTM) | €915.04k |
Is XLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XLS income statement (TTM) | |
|---|---|
| Revenue | CHF 839.38k |
| Cost of Revenue | CHF 317.52k |
| Gross Profit | CHF 521.86k |
| Other Expenses | -CHF 30.23m |
| Earnings | CHF 30.75m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Apr 28, 2026
| Earnings per share (EPS) | 5.33 |
| Gross Margin | 62.17% |
| Net Profit Margin | 3,663.79% |
| Debt/Equity Ratio | 15.0% |
How did XLS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/05 10:46 |
| End of Day Share Price | 2026/02/04 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Xlife Sciences AG is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniel Jelovcan | Stifel, Equities Research |
| Ulrich Huwald | Warburg Research GmbH |